We really need to look into the story behind this Y-to -Y 15% sale drop, the whole quarter is under full impact of FDA new labeling request and many speculative legal actions from the lawyers.
The sale figure is not that bad considering all of these factors.
Important: Axiron' market share is still consistent.
- Forums
- ASX - By Stock
- Ann: Axiron Net Sales, quarter to June 2015
ACR
acrux limited
Add to My Watchlist
6.25%
!
1.7¢

We really need to look into the story behind this Y-to -Y 15%...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.7¢ |
Change
0.001(6.25%) |
Mkt cap ! $6.931M |
Open | High | Low | Value | Volume |
1.6¢ | 1.7¢ | 1.6¢ | $6.279K | 376.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 741559 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 193057 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 741559 | 0.016 |
6 | 1259314 | 0.015 |
3 | 420000 | 0.014 |
2 | 397000 | 0.013 |
1 | 80000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 153057 | 1 |
0.018 | 252359 | 2 |
0.019 | 677115 | 3 |
0.020 | 50000 | 1 |
0.021 | 203466 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online